1. Home
  2. RTX vs REGN Comparison

RTX vs REGN Comparison

Compare RTX & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RTX
  • REGN
  • Stock Information
  • Founded
  • RTX 1934
  • REGN 1988
  • Country
  • RTX United States
  • REGN United States
  • Employees
  • RTX N/A
  • REGN N/A
  • Industry
  • RTX Aerospace
  • REGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • RTX Industrials
  • REGN Health Care
  • Exchange
  • RTX Nasdaq
  • REGN Nasdaq
  • Market Cap
  • RTX 172.4B
  • REGN 56.7B
  • IPO Year
  • RTX N/A
  • REGN 1991
  • Fundamental
  • Price
  • RTX $146.83
  • REGN $567.74
  • Analyst Decision
  • RTX Buy
  • REGN Buy
  • Analyst Count
  • RTX 14
  • REGN 22
  • Target Price
  • RTX $141.21
  • REGN $840.95
  • AVG Volume (30 Days)
  • RTX 6.1M
  • REGN 987.0K
  • Earning Date
  • RTX 07-22-2025
  • REGN 08-01-2025
  • Dividend Yield
  • RTX 1.85%
  • REGN 0.62%
  • EPS Growth
  • RTX 37.34
  • REGN 16.49
  • EPS
  • RTX 3.41
  • REGN 39.43
  • Revenue
  • RTX $81,739,000,000.00
  • REGN $14,085,700,000.00
  • Revenue This Year
  • RTX $5.40
  • REGN N/A
  • Revenue Next Year
  • RTX $5.96
  • REGN $6.77
  • P/E Ratio
  • RTX $43.02
  • REGN $14.40
  • Revenue Growth
  • RTX 15.11
  • REGN 7.52
  • 52 Week Low
  • RTX $100.22
  • REGN $476.49
  • 52 Week High
  • RTX $149.26
  • REGN $1,211.20
  • Technical
  • Relative Strength Index (RSI)
  • RTX 61.80
  • REGN 63.13
  • Support Level
  • RTX $142.98
  • REGN $532.60
  • Resistance Level
  • RTX $146.78
  • REGN $559.46
  • Average True Range (ATR)
  • RTX 2.16
  • REGN 14.29
  • MACD
  • RTX -0.23
  • REGN 6.52
  • Stochastic Oscillator
  • RTX 96.29
  • REGN 98.82

About RTX RTX Corporation

RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace and to the defense market across three segments: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: